ClinicalTrials.gg
RecruitingNCT07507513Updated Jul 28, 2026

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

A Phase 2 interventional study of 627 and Placebo in Ulcerative Colitis (UC), sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
35th of 136
288 · median 121
Started
2026
with 27 others
Phase 2
35 of 184
15 open now
Primary completion
2029-02
later than 87 of 95 live
Registered
161st of 184
by date

Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 35th largest by planned enrollment of the 136 interventional ones that give a count, is one of 28 that started in 2026, is one of 35 in phase 2, reaches primary completion later than 87 of the 95 other live ones, and was the 161st registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of 627 in patients with UC.

Read the detailed description

Ulcerative colitis (UC) is a chronic non-specific intestinal disease characterized by continuous and diffuse inflammatory changes in the colorectal mucosa. Despite the availability of advanced therapies, there remains a significant unmet medical need, such as inadequate or loss of response to one or more of the following therapies, corticosteroid dependence, or intolerance to one or more therapies. The purpose of this study is to evaluate the efficacy and safety of 627 in patients with moderate to severe UC.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and comply with the requirements of the study protocol, and sign the written form (ICF).
  2. Male or female subjects aged 18-75 years old when signing the ICF.
  3. Subjects must have been diagnosed with UC for at least 3 months prior to randomization.
  4. Moderate to Severe Active Ulcerative Colitis (UC).
  5. Inadequate or lost response, intolerance to one or more therapies, or dependence.
  6. Female subjects of and male subjects (and their female partners) must use highly effective from the screening period through at least 6 months after the last dose. The subjects must have no plans for pregnancy, sperm donation, or oocyte donation during the same period (from screening through at least 6 months post-last dose).

Exclusion criteria

Exclusion Criteria:

  1. History of severe opportunistic infection within 2 months prior to screening or randomization that remains not adequately controlled.
  2. Receiving protocol-prohibited treatments prior to screening or randomization.
  3. Presence of any laboratory test abnormalities during screening and/or determination by the investigator that enrollment in the study may pose uncontrollable safety risks to the subject.
  4. Positive test result, positive virus antibody (HCV Ab), positive antibody (HIV Ab), or positive serum Treponema pallidum antibody (TP Ab) during screening, as specified in the protocol.
  5. History of cardiovascular and cerebrovascular diseases within 6 months prior to screening.
  6. History of any within 5 years prior to screening or currently active malignancy.
  7. Allergy to the medicinal product, any of its components, or .
  8. History of alcohol or substance abuse within 6 months prior to screening.
  9. Undergone major surgery within 6 months prior to screening or planned major surgery during the study period.
  10. Blood donation or significant blood loss within 4 weeks prior to screening.
  11. Participation in any drug clinical trial within 3 months prior to screening or within 5 half-lives of the investigational drug (whichever is longer).
  12. Vaccination with live/attenuated within 4 weeks prior to screening or planned vaccination during the study period.
  13. Pregnant or lactating female subjects.
  14. Other conditions deemed unsuitable for trial participation by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    Group M1

    dose level 1 of 627

    Drug: 627 · Drug: Placebo

  • Experimental
    Group M2

    dose level 2 of 627

    Drug: 627 · Drug: Placebo

  • Experimental
    Group M3

    dose level 3 of 627

    Drug: 627 · Drug: Placebo

  • Experimental
    Group M4

    dose level 4 of 627

    Drug: 627 · Drug: Placebo

  • Experimental
    Group A

    627 Dose A subcutaneous (SC) injection.

    Drug: 627

  • Experimental
    Group B

    627 Dose B subcutaneous (SC) injection.

    Drug: 627

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

  • Experimental
    Group C

    627 subcutaneous (SC) injection.

    Drug: 627

Interventions

  • Drug627

    627 subcutaneous (SC) injection.

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    Time frame: During the 36-week study period

Secondary outcomes

  1. Clinical remission based on Mayo Score (MMS)

    Proportion of subjects achieving clinical remission based on Mayo Score (MMS) (Rectal Bleeding Score \[RBS\] = 0, Endoscopic Score \[ES\] ≤ 1 without friability, and Stool Frequency Score \[SFS\] ≤ 1and not exceeding baseline).

    Time frame: Week 14

  2. Clinical response based on Mayo Score (MMS)

    Proportion of subjects achieving clinical response based on Mayo Score (MMS) (≥2-point and ≥30% reduction in MMS from baseline, and ≥1-point reduction in Rectal Bleeding Score \[RBS\] or RBS value ≤1 point).

    Time frame: Week 14

  3. Endoscopic improvement

    Proportion of subjects achieving endoscopic improvement (Endoscopic Score \[ES\] ≤ 1 without friability).

    Time frame: Week 14

  4. Endoscopic remission

    Proportion of subjects achieving endoscopic remission (Endoscopic Score \[ES\] = 0).

    Time frame: Week 14

  5. Symptomatic remission

    Proportion of subjects achieving symptomatic remission (Rectal Bleeding Score \[RBS\] = 0 and Stool Frequency Score \[SFS\] = 0).

    Time frame: During the 36-week study period

  6. Symptomatic response

    Proportion of subjects achieving symptomatic response (≥30% reduction from baseline in combined RBS and SFS total scores).

    Time frame: During the 36-week study period

  7. Time to achievement of symptomatic remission and symptomatic response

    Time frame: During the 36-week study period

Other outcomes

  1. Peak Plasma Concentration (Cmax).

    Time frame: During the 36-week study period

  2. Area under the Concentration-Time Curve up to the Last Measurable Concentration (AUC 0-last).

    Time frame: During the 36-week study period.

  3. Time to Peak Concentration (Tmax).

    Time frame: During the 36-week study period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2029, 35 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 35 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 2, 2026
StartActual
Mar 28, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Dec 30, 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507513
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Mar 28, 2026
Primary completion
Feb 28, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Qinghong Zhou
Contact
zhouqinghong@3sbio.com
+86 18911301578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion